CHICAGO, December 30, 2022 — As the leading voluntary health organization in Alzheimer’s care, support and research, a main focus of the Alzheimer’s Association’s work is ensuring access to high-quality treatment and care. In the coming year, the Food and Drug Administration (FDA) may approve additional treatments that could have an unequivocally meaningful impact on people in the earliest stages of this deadly disease. Approval is the fundamental first step, followed immediately by access. Equitable access can only be achieved if treatments are priced appropriately. If pharmaceutical companies set the cost of treatments too high and if payers are unwilling to cover them, treatments will only be available for those who can afford to pay out-of-pocket. The majority of those who desperately need these independence-sustaining treatments will not be able to get them, resulting in continued irreversible disease progression — erasing memories, hope and time.

About the Alzheimer's Association

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.